Patents by Inventor Florence Boudet

Florence Boudet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VACCINES AGAINST SARS-COV-2 INFECTIONS
    Publication number: 20240016918
    Abstract: Provided are novel vaccines for prophylactic treatment of SARS-CoV-2 infections and COVID-19 and methods of making the vaccines.
    Type: Application
    Filed: August 23, 2021
    Publication date: January 18, 2024
    Applicant: SANOFI PASTEUR INC.
    Inventors: Natalie ANOSOVA, Salvador Fernando AUSAR, Catherine BERRY, Florence BOUDET, Danilo CASIMIRO, Roman M. CHICZ, Gustavo DAYAN, Guy DE BRUYN, Carlos DIAZGRANADOS, Tong-Ming FU, Marie GARINOT, Lorry GRADY, Sanjay GURUNATHAN, Kirill KALNIN, Nikolai KHRAMTSOV, Valérie LECOUTURIER, Nausheen RAHMAN, Sophie RUIZ, Stephen SAVARINO, Saranya SRIDHAR, Indresh K. SRIVASTAVA, James TARTAGLIA, Timothy TIBBITTS
  • Methods for inducing HIV-neutralizing antibodies
    Patent number: 7056519
    Abstract: The present invention relates to a method for inducing antibodies neutralizing HIV primary isolates in a mammal, comprising administration of a pharmaceutical composition comprising a polypeptide represented by the formula N-L-C, in which: N represents the amino acid sequence 25–81 of gp41, C represents the amino acid sequence 112–157 of gp41, and L represents a flexible linking sequence comprising from 2 to 30 amino acids.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: June 6, 2006
    Assignee: Aventis Pasteur S.A.
    Inventors: Florence Boudet, Raphaëlle El Habib, Tino Krell, Régis Sodoyer, Michel Chevalier
  • Polypeptide antigen inducing HIV-neutralizing antibodies
    Publication number: 20040009188
    Abstract: The present invention relates to a method for inducing antibodies neutralizing HIV primary isolates in a mammal, comprising administration of a pharmaceutical composition comprising a polypeptide represented by the formula N-L-C, in which:
    Type: Application
    Filed: May 15, 2003
    Publication date: January 15, 2004
    Inventors: Florence Boudet, Raphaelle EL Habib, Tino Krell, Regis Sodoyer, Michel Chevalier
  • Chemically modified hiv envelope glycoprotein
    Publication number: 20030099934
    Abstract: The present invention relates to an envelope glycoprotein of HIV in purified form which can be obtained by a method comprising the following steps: (1) production of an envelope glycoprotein in purified form, (2) reduction of at least one disulfide bridge of the glycoprotein of step (1), (3) alkylation of at least two free sulfhydryl groups, (4) optionally, oxidation of the remaining free sulfhydryl groups, (5) denaturation and (6) renaturation, and to its use in a vaccine against HIV which can be used for inducing antibodies which neutralize HIV in a human individual, therapeutically or prophylactically.
    Type: Application
    Filed: November 18, 2002
    Publication date: May 29, 2003
    Inventors: Florence Boudet, Michel Chevalier, Jean Dubayle, Raphaelle El Habib